COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, has changes its name effective August 6, 2024.
 
The shareholders of the company approved a special resolution authorizing the board of directors of the company to effect the name change. There is no change in the capitalization of the Company in connection with the name change.
 
One of COSCIENS’ lead products is macimorelin, (Macrilen; Ghryvelin) the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). COSCIENS is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.